source
- Eli Lilly's Alzheimer's drug mevidalen fails Phase 2 trialEli Lilly conducted a Phase 2 trial of mevidalen, a dopamine-modulating compound, in patients with mild to moderate Alzheimer's disease. The study did not meet its primary efficacy endpoints, indi…
- White House withdraws Heidi Overton’s FDA commissioner nomination amid Senate oppositionThe White House pulled the nomination of Heidi Overton for FDA commissioner just hours before the Senate Health, Education, Labor, and Pensions (HELP) committee was set to vote. Overton, who serve…